We recognize that the MCF7 ER+ breast cancer cell line does not well represent all of the heterogeneous 641 breast tumor tissue samples that we used, and thus the MCF7 ChIP-seq data cannot validate all of the tumor-specific enhancers we identified. This evidence concerns the gene ESR1 and breast cancer.